USMLE Prep - Medical Reference Library

Dry Eye Disease — Evaluation & Treatment

System: Ophthalmology • Reviewed: Aug 31, 2025 • Step 1Step 2Step 3

Synopsis:

Multifactorial disease of tear film and ocular surface. Stage severity; treat with lubricants, anti‑inflammatories (cyclosporine/lifitegrast), lid hygiene/MGD therapy, and punctal occlusion in select cases.

Key Points

  • Stabilize ABCs; begin targeted evaluation without delaying life-saving therapy.
  • Use system-specific risk tools to guide testing and disposition.
  • Order high-yield tests first; escalate imaging when indicated.
  • Start evidence-based initial therapy and reassess frequently.

Algorithm

  1. Primary survey and vitals; IV access and monitors.
  2. Focused history/physical; identify red flags and likely etiologies.
  3. Order system-appropriate labs and imaging (see Investigations).
  4. Initiate guideline-based empiric therapy (see Pharmacology).
  5. Reassess response; arrange consultation and definitive management.

Clinical Synopsis & Reasoning

For Dry Eye Disease Evaluation Treatment, frame the differential by acuity and pathophysiology, then align diagnostics to the leading hypotheses. Prioritize stabilization while obtaining high‑yield studies such as CBC (Baseline hematology), BMP (Electrolytes/renal). Incorporate bedside imaging and targeted labs to define severity and identify complications; synthesize results with clinical trajectory to refine the working diagnosis and disposition needs.


Treatment Strategy & Disposition

Initiate disease‑directed therapy alongside supportive care, titrating to objective response. Pharmacologic options commonly include Analgesia/Antipyretics. Use validated frameworks (e.g., Staged Therapy) to guide escalation and site of care. Address precipitating factors, de‑escalate empiric therapies with data, and arrange follow‑up for monitoring and risk‑factor modification; admit patients with instability, high risk of deterioration, or needs for close monitoring.


Management Notes

Check for Sjögren’s in severe aqueous deficiency (SSA/SSB, salivary gland symptoms).


Epidemiology / Risk Factors

  • Risk factors vary by condition and patient profile

Investigations

TestRole / RationaleTypical FindingsNotes
CBCBaseline hematologyAbnormal counts
BMPElectrolytes/renalDerangements

Staged Therapy

StepInterventions
1PF tears, lifestyle, lid hygiene
2Cyclosporine/lifitegrast, short steroid pulse
3Punctal plugs, thermal pulsation
4Autologous serum tears, scleral lenses
ComorbidTreat blepharitis/rosacea

Pharmacology

MedicationMechanismOnsetRole in TherapyLimitations
Erythromycin ointment (prophylaxis)AntibacterialHoursSurface protection if corneal epithelial defectAllergy
Cyclopentolate (gtt)CycloplegicMinutesPain control for ciliary spasmBlurred vision
Prednisolone acetate (gtt) (if indicated)Topical steroidHoursInflammatory conditions per ophtho↑ IOP

Prognosis / Complications

  • Prognosis depends on severity, comorbidities, and timeliness of care

Patient Education / Counseling

  • Explain red flags and when to seek emergent care.
  • Reinforce medication adherence and follow-up plan.

References

  1. DEWS II Guidelines — Link